Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia

The acute myeloid leukemia (AML) patients obtain limited benefits from current immune checkpoint blockades (ICBs), although immunotherapy have achieved encouraging success in numerous cancers. Here, we found that V-domain Ig suppressor of T cell activation (VISTA), a novel immune checkpoint, is high...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Jianshan, Deng, Lin, Peng, Keren, Ouyang, Shumin, Ding, Wen, Lou, Linlin, Lin, Ziyou, Zhu, Jianzheng, Li, Jingwei, Zhang, Qiyi, Wang, Pengyan, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Lu, Jin-Jian, Zhu, Kai, Zheng, Yongjiang, Wang, Yuanxiang, Zhang, Xiaolei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969711/
https://www.ncbi.nlm.nih.gov/pubmed/36849939
http://dx.doi.org/10.1186/s13045-023-01410-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969711/
https://www.ncbi.nlm.nih.gov/pubmed/36849939
http://dx.doi.org/10.1186/s13045-023-01410-y

Ejemplares similares